Fractyl Health, Inc. (NASDAQ:GUTS) Receives $5.40 Average Target Price from Analysts

Shares of Fractyl Health, Inc. (NASDAQ:GUTS) have earned an average recommendation of “Hold” from the five brokerages that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $5.40.

A number of research firms have recently issued reports on GUTS. Wall Street Zen upgraded shares of Fractyl Health from a “strong sell” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Fractyl Health in a research note on Tuesday, May 12th. Canaccord Genuity Group reiterated a “buy” rating and set a $8.00 price objective on shares of Fractyl Health in a research note on Thursday, March 26th. Finally, HC Wainwright reiterated a “buy” rating and set a $8.00 price objective on shares of Fractyl Health in a research note on Thursday, June 4th.

Fractyl Health Price Performance

NASDAQ GUTS opened at $0.85 on Wednesday. The company has a debt-to-equity ratio of 1.41, a quick ratio of 4.28 and a current ratio of 4.28. The firm’s 50 day moving average price is $0.69 and its 200-day moving average price is $1.07. Fractyl Health has a 52-week low of $0.38 and a 52-week high of $2.45. The company has a market cap of $134.85 million, a PE ratio of -0.66 and a beta of 2.34.

Fractyl Health (NASDAQ:GUTS) last released its quarterly earnings data on Tuesday, May 12th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.23. Sell-side analysts forecast that Fractyl Health will post -0.6 EPS for the current fiscal year.

Insider Activity at Fractyl Health

In other news, Director Ian Sheffield bought 35,000 shares of the stock in a transaction on Wednesday, June 10th. The stock was bought at an average cost of $0.73 per share, for a total transaction of $25,550.00. Following the completion of the purchase, the director directly owned 35,000 shares in the company, valued at approximately $25,550. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director William Bradley bought 68,493 shares of the stock in a transaction on Wednesday, June 10th. The stock was purchased at an average price of $0.73 per share, with a total value of $49,999.89. Following the completion of the purchase, the director owned 84,622 shares of the company’s stock, valued at $61,774.06. This represents a 424.66% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders acquired 148,493 shares of company stock valued at $107,600. 8.52% of the stock is owned by insiders.

Institutional Investors Weigh In On Fractyl Health

Several institutional investors have recently bought and sold shares of the company. Nantahala Capital Management LLC acquired a new stake in Fractyl Health in the third quarter valued at approximately $19,298,000. 683 Capital Management LLC boosted its stake in Fractyl Health by 30.1% in the fourth quarter. 683 Capital Management LLC now owns 6,047,620 shares of the company’s stock valued at $13,305,000 after acquiring an additional 1,397,620 shares in the last quarter. Marshall Wace LLP boosted its stake in Fractyl Health by 234.9% in the fourth quarter. Marshall Wace LLP now owns 5,926,745 shares of the company’s stock valued at $13,039,000 after acquiring an additional 4,156,969 shares in the last quarter. Pale Fire Capital SE boosted its stake in Fractyl Health by 84.5% in the first quarter. Pale Fire Capital SE now owns 5,921,045 shares of the company’s stock valued at $2,711,000 after acquiring an additional 2,711,103 shares in the last quarter. Finally, Alyeska Investment Group L.P. acquired a new stake in Fractyl Health in the third quarter valued at approximately $8,981,000.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.